Dianthus Therapeutics, Inc. (Nasdaq: DNTH) announced the pricing of its upsized underwritten public offering, expecting to raise approximately $251 million. The offering includes 6,487,879 shares of common stock and pre-funded warrants to purchase additional shares. The company plans to use the proceeds for development activities and general corporate purposes. The offering is expected to close on September 11, 2025. Jefferies, TD Cowen, Evercore ISI, and Stifel are acting as joint book-running managers. Dianthus is focused on developing monoclonal antibodies for severe autoimmune diseases.

A shelf registration statement was filed with the SEC, and the offering is being made through a prospectus supplement. Forward-looking statements in the press release highlight potential risks and uncertainties. Dianthus aims to deliver transformative medicines for autoimmune and inflammatory diseases. The company will continue to update on progress and developments in the future. For more information, contact Jennifer Davis Ruff at [email protected].

Read more at GlobeNewswire: Dianthus Therapeutics, Inc. Announces Pricing of Upsized